Regulatory Updates In WA & NJ – Summarized | Cannabis Law Report | How to order Skittles Moonrock online

Learn where to buy CBD Oil online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Microdose write

The State of Psychedelics: Updates in WA and NJ

Washington State’s legislative session kicked off this week, and numerous psychedelic bills are in the mix. Senate Bill 5201 and House Bill 1433 both propose a state-regulated psychedelic services program similar to those in Oregon and Colorado. The same bills were introduced in the 2025 legislative but neither moved forward and so they’ve been reintroduced.

A third bill, Senate Bill 5921 also proposes a psilocybin program, but one that would be overseen by the Department of Health and focused on medical use only. The bill was drafted by the Coalition for Better Community Health, which includes Tom Eckert, one of the architects of Oregon’s psilocybin services ballot initiative, University of Washington psychedelics researcher Nathan Sackett, Americans for Ibogaine’s Bryan Hubbard, and Healing Advocacy Fund’s executive director Taylor West. The bill was proposed by Jesse Salomon (D), who also proposed SB 5201.

Meanwhile, local advocacy group REACH WA is also trying to get another psychedelics bill off the ground in Washington State. Their draft bill, for which the group is currently seeking a sponsor in the legislature, would allow people over 21 to access services to support natural psychedelic use, allow personal possession, use, cultivation, preparation, and gifting of psilocybin, psilocin, DMT, and mescaline (excluding peyote), establish rules about advertising such services, and require psychedelic businesses to retain majority Washington state residency through 2029.

On Monday, the last day of its legislative sessions, the New Jersey Senate passed bill S2283, which will provide $6 million from the state’s general fund to a two-year pilot program to conduct psilocybin research. The bill passed the assembly 48-23, then the senate 35-4. It now awaits a signature by Governor Phil Murphy.

At a New Jersey State Assembly Appropriations Committee hearing about the bill in December, members of the public raised concerns that the allotted $6 million would end up going to psychedelics companies conducting clinical trials with synthetic psilocybin (i.e., Compass Pathways, which is already partnering with New Jersey healthcare system Hackensack Meridian). People were also worried that the bill’s language did not explicitly mention preparation and integration sessions for study participants. The final version of the bill has amendments that explicitly include integration and require applicants for the research grants to include hospitals from each region of the state.